Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2024

Open Access 24-02-2024 | Melanoma | Case Report

Primary endobronchial melanoma: a case report and clinical management indications

Authors: Emanuela Barisione, Andrea Boutros, Marco Mora, Francesco Spagnolo, Enrica Teresa Tanda, Carlo Genova, Elena Tagliabue

Published in: BMC Pulmonary Medicine | Issue 1/2024

Login to get access

Abstract

Background

While cutaneous melanomas are well-documented, primary melanoma of the lung (PMML), particularly with endobronchial origin, remains rare and poorly characterized. This case report addresses gaps in understanding by presenting a comprehensive case of a 71-year-old male with primary endobronchial melanoma and conducting a systematic review of PMML cases.

Case Presentation

The patient, a former smoker, presented with dyspnea, cough, and hemoptysis. Imaging revealed left lung atelectasis and a suspicious nodule. Bronchoscopy identified an endobronchial mass, subsequently treated with argon plasma coagulation and resection. Biopsy confirmed melanoma. Extensive examinations ruled out a primary skin lesion. Despite initial treatment, recurrence led to pneumonectomy. Histopathology confirmed melanoma. The patient received treatment with pembrolizumab and ipilimumab, but with poor clinical benefit.

Conclusions

Primary endobronchial melanoma is a rare entity, comprising 0.01% of lung tumors. This case underscores diagnostic challenges and emphasizes histological criteria to distinguish primary from metastatic lesions. The pathogenesis remains unclear, with theories proposing foetal melanocyte migration or squamous metaplasia. Prognosis varies, necessitating radical surgical extirpation. A systematic review revealed diverse outcomes, supporting the need for further research. In conclusion, endobronchial melanoma involves an endoscopic and surgical management, but evolving therapies, such as immunotherapy, may reshape treatment paradigms. This case contributes to our understanding of PMML, guiding future research and clinical management. As therapeutic options evolve, continued research is crucial to refine our understanding and improve outcomes for this rare malignancy.
Literature
7.
go back to reference Dasgupta TK, Brasfield RD, Paglia MA. Primary melanomas in unusua sites. Surg Gynecol Obstet. 1969;128:841–8.PubMed Dasgupta TK, Brasfield RD, Paglia MA. Primary melanomas in unusua sites. Surg Gynecol Obstet. 1969;128:841–8.PubMed
19.
29.
35.
go back to reference Zimmer L, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C, et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;395:1558–68. https://doi.org/10.1016/S0140-6736(20)30417-7.CrossRefPubMed Zimmer L, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C, et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;395:1558–68. https://​doi.​org/​10.​1016/​S0140-6736(20)30417-7.CrossRefPubMed
Metadata
Title
Primary endobronchial melanoma: a case report and clinical management indications
Authors
Emanuela Barisione
Andrea Boutros
Marco Mora
Francesco Spagnolo
Enrica Teresa Tanda
Carlo Genova
Elena Tagliabue
Publication date
24-02-2024
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-024-02904-2

Other articles of this Issue 1/2024

BMC Pulmonary Medicine 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine